DBV Technologies (DBVT) to Release Earnings on Tuesday

DBV Technologies (NASDAQ:DBVT) will be announcing its earnings results after the market closes on Tuesday, July 30th. Analysts expect the company to announce earnings of ($0.26) per share for the quarter.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Tuesday, May 7th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.16. DBV Technologies had a negative net margin of 530.89% and a negative return on equity of 56.76%. The firm had revenue of $1.41 million for the quarter, compared to analyst estimates of $3.20 million. On average, analysts expect DBV Technologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

DBV Technologies Trading Up 1.3 %

DBVT stock traded up $0.01 during mid-day trading on Monday, hitting $0.94. The stock had a trading volume of 1,065 shares, compared to its average volume of 55,922. DBV Technologies has a 52 week low of $0.50 and a 52 week high of $3.70. The firm has a market capitalization of $91.13 million, a P/E ratio of -1.11 and a beta of 0.69. The firm has a fifty day simple moving average of $0.94 and a 200 day simple moving average of $1.34.

Wall Street Analyst Weigh In

Several equities analysts have commented on DBVT shares. HC Wainwright decreased their target price on shares of DBV Technologies from $20.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. StockNews.com assumed coverage on shares of DBV Technologies in a research report on Thursday. They set a “hold” rating on the stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.